DBV Technologies Announces Initiation of Phase III Study of Viaskin(r) Peanut for the Treatment of Peanut Allergic Children
DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced the initiation of a pivotal Phase III study designed to evaluate the safety and efficacy of Viaskin® Peanut 250 micrograms in children ages 4 to 11 with peanut allergy. Click here for more details.
Though one of the most popular and recognizable “nuts” in the United States, peanuts are actually not true nuts. Rather, they are the shell-enclosed seeds of a plant that’s related to peas and beans. Click here for more details.
Agriculture Secretary Tom Vilsack has appointed three producers and three industry representatives to serve on the Peanut Standards Board. All six members will serve on the board through June 30, 2018. Their appointments are effective immediately. Click here for more details.